AAAAAA

   
Results: 1-9 |
Results: 9
Characterization of the pharmacology, signal transduction and internalization of the fluorescent PACAP ligand, fluor-PACAP, on NIH/3T3 cells expressing PAC1
Authors: Germano, PM Stalter, J Le, SV Wu, M Yamaguchi, DJ Scott, D Pisegna, JR
Citation: Pm. Germano et al., Characterization of the pharmacology, signal transduction and internalization of the fluorescent PACAP ligand, fluor-PACAP, on NIH/3T3 cells expressing PAC1, PEPTIDES, 22(6), 2001, pp. 861-866
Switching between intravenous and oral pantoprazole
Authors: Pisegna, JR
Citation: Jr. Pisegna, Switching between intravenous and oral pantoprazole, J CLIN GAST, 32(1), 2001, pp. 27-32
Identification of an essential amino acid motif within the C terminus of the pituitary adenylate cyclase-activating polypeptide type I receptor that is critical for signal transduction but not for receptor internalization
Authors: Lyu, RM Germano, PM Choi, JK Le, SV Pisegna, JR
Citation: Rm. Lyu et al., Identification of an essential amino acid motif within the C terminus of the pituitary adenylate cyclase-activating polypeptide type I receptor that is critical for signal transduction but not for receptor internalization, J BIOL CHEM, 275(46), 2000, pp. 36134-36142
Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome
Authors: Lew, EA Pisegna, JR Starr, JA Soffer, EF Forsmark, C Modlin, IM Walsh, JH Beg, M Bochenek, W Metz, DC
Citation: Ea. Lew et al., Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome, GASTROENTY, 118(4), 2000, pp. 696-704
Salivary and gastric epidermal growth factor in patients with Zollinger-Ellison Syndrome: Its protective potential
Authors: Sarosiek, J Jensen, RT Maton, PN Peura, DA Harlow, D Feng, TQ McCallum, RW Pisegna, JR
Citation: J. Sarosiek et al., Salivary and gastric epidermal growth factor in patients with Zollinger-Ellison Syndrome: Its protective potential, AM J GASTRO, 95(5), 2000, pp. 1158-1165
Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease
Authors: Metz, DC Pratha, V Martin, P Paul, J Maton, PN Lew, E Pisegna, JR
Citation: Dc. Metz et al., Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease, AM J GASTRO, 95(3), 2000, pp. 626-633
PACAP type I receptor activation regulates ECL cells and gastric acid secretion
Authors: Zeng, NX Athmann, C Kang, T Lyu, RM Walsh, JH Ohning, GV Sachs, G Pisegna, JR
Citation: Nx. Zeng et al., PACAP type I receptor activation regulates ECL cells and gastric acid secretion, J CLIN INV, 104(10), 1999, pp. 1383-1391
Adenocarcinoma of the colon with neuroendocrine features and secretory diarrhea
Authors: Lew, EA Lewin, KJ Zarchy, T Pisegna, JR
Citation: Ea. Lew et al., Adenocarcinoma of the colon with neuroendocrine features and secretory diarrhea, AM J GASTRO, 94(6), 1999, pp. 1692-1694
Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: A dose-response study
Authors: Pisegna, JR Martin, P McKeand, W Ohning, G Walsh, JH Paul, J
Citation: Jr. Pisegna et al., Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: A dose-response study, AM J GASTRO, 94(10), 1999, pp. 2874-2880
Risultati: 1-9 |